During the recent European Respiratory Society (ERS) conference held in Vienna, Prof. Capucine Morelot-Panzini, Head of Pneumonology at Pitié-Salpêtrière Hospital and Professor at Sorbonne University, presented the positive results of the COVA phase 2/3 trial on 20-hydroxyecdysone (BIO101) for the treatment of hospitalized severe COVID-19 patients.
Her presentation highlighted a statistically significant reduction in the relative risk of early death or respiratory failure, as well as a nominal reduction in the mortality rate at day 90, positioning 20E (BIO101) as a promising therapeutic option for severe COVID-19 cases, especially for older adults with comorbidities.